- Home
- RDVT vs TRML Comparison
RDVT vs TRML Comparison
Compare RDVT & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDVT
- TRML
- Stock Information
- Founded
- RDVT 2017
- TRML 2021
- Country
- RDVT United States
- TRML United States
- Employees
- RDVT N/A
- TRML N/A
- Industry
- RDVT Computer Software: Prepackaged Software
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- RDVT Technology
- TRML Health Care
- Exchange
- RDVT Nasdaq
- TRML Nasdaq
- Market Cap
- RDVT 606.7M
- TRML 598.9M
- IPO Year
- RDVT N/A
- TRML N/A
- Fundamental
- Price
- RDVT $48.99
- TRML $47.69
- Analyst Decision
- RDVT
- TRML Hold
- Analyst Count
- RDVT 0
- TRML 12
- Target Price
- RDVT N/A
- TRML $47.04
- AVG Volume (30 Days)
- RDVT 96.2K
- TRML 1.6M
- Earning Date
- RDVT 11-05-2025
- TRML 11-06-2025
- Dividend Yield
- RDVT 0.61%
- TRML N/A
- EPS Growth
- RDVT N/A
- TRML N/A
- EPS
- RDVT 0.61
- TRML N/A
- Revenue
- RDVT $82,399,000.00
- TRML N/A
- Revenue This Year
- RDVT $19.34
- TRML N/A
- Revenue Next Year
- RDVT $13.60
- TRML N/A
- P/E Ratio
- RDVT $79.69
- TRML N/A
- Revenue Growth
- RDVT 22.14
- TRML N/A
- 52 Week Low
- RDVT $25.37
- TRML $11.56
- 52 Week High
- RDVT $54.19
- TRML $47.70
- Technical
- Relative Strength Index (RSI)
- RDVT 54.58
- TRML 59.15
- Support Level
- RDVT $47.13
- TRML N/A
- Resistance Level
- RDVT $51.47
- TRML $47.70
- Average True Range (ATR)
- RDVT 1.82
- TRML 1.08
- MACD
- RDVT -0.16
- TRML 0.52
- Stochastic Oscillator
- RDVT 26.27
- TRML 99.94
About RDVT Red Violet Inc.
Red Violet Inc is a software and services company. It specializes in data analysis, providing cloud-based, mission-critical information solutions to enterprises in a variety of industries. Through its CORE data fusion platform, it provides mission-critical information about individuals, businesses and assets.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.